Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Teclistamab Safe for Treating Patients with R/R MM with Renal Impairment
Thomas R. Collins
Study of LBCL Confirms Prognostic Value of ctDNA in Second-Line Liso-Cel Versus Standard of Care
Katie Robinson
Extramedullary Disease Helps Predict Immune Effector Cell Toxicities After CAR-T in MM
Thomas R. Collins
Clonal Hematopoiesis May Prolong Cytopenias After CAR-T Therapy for MM
Katie Robinson
CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study
Katie Robinson
Physical Function Can Help Gauge ICANS Risk, Study Finds
Thomas R. Collins
Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM
Lara C. Pullen, PhD
Cilta-Cel Achieves Rapid, Sustained MRD Negativity in Lenalidomide-Refractory MM as Early as First Relapse
Katie Robinson
Study Illuminates Clinical Characteristics, Molecular Origin of Post-CAR-T Treatment–Related Myeloid Neoplasms
Katie Robinson
IL-15 Agonist Boosts Response in Phase II LBCL CAR-T Trial
Thomas R. Collins
Predicting Response to Obe-Cel in Patients With R/R B-ALL
Lara C. Pullen, PhD
Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups
Katie Robinson
Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab
Lara C. Pullen, PhD
Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma
Anna Azvolinsky, PhD
Initial Results Confirm Safety of Lower-Dose Teclistamab as Maintenance in NDMM
Khylia Marshall
Teclistamab-Based Induction Regimens Achieve MRD Negativity in Patients With Transplant-Eligible NDMM
Katie Robinson
Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma
Lara C. Pullen, PhD
Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL
Anna Azvolinsky, PhD
High Incidence of Postpartum Hemorrhage Seen in Hemophilia Carriers
Ruth Jessen Hickman, MD
Pomalidomide Found Safe, Highly Effective for Epistaxis in HHT
Ruth Jessen Hickman, MD

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
February 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals